Vevye FDA Approval History
Last updated by Judith Stewart, BPharm on June 9, 2023.
FDA Approved: Yes (First approved May 30, 2023)
Brand name: Vevye
Generic name: cyclosporine
Dosage form: Ophthalmic Solution
Previous Name: CyclASol
Company: Novaliq Inc.
Treatment for: Dry Eye Disease
Vevye (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of the signs and symptoms of dry eye disease.
- Dry eye disease is an inflammatory ocular surface disorder that can cause progressive corneal surface damage that can lead to direct or indirect visual impairment.
- Vevye contains cyclosporine, an anti-inflammatory, immunomodulating drug that works by treating the underlying inflammatory root cause of dry eye disease.
- Vevye is formulated with EyeSol®, a water-free technology that enables a high bio-availability of the active drug in the target tissues, and an increased residual time on the ocular surface.
- Vevye is administered into each eye twice a day, approximately every 12 hours.
- Common adverse reactions include instillation site reactions.
Development timeline for Vevye
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
